Dallah Healthcare Full Year 2023 Earnings: EPS Beats Expectations

Dallah Healthcare (TADAWUL:4004) Full Year 2023 Results

Key Financial Results

• Revenue: ر.س2.94b (up 18% from FY 2022).
• Net income: ر.س360.1m (up 31% from FY 2022).
• Profit margin: 12% (up from 11% in FY 2022). The increase in margin was driven by higher revenue.
• EPS: ر.س3.70 (up from ر.س3.05 in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Dallah Healthcare EPS Beats Expectations

Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 5.7%.

The primary driver behind last 12 months revenue was the Medical Services segment contributing a total revenue of ر.س2.81b (95% of total revenue). Notably, cost of sales worth ر.س1.92b amounted to 65% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to ر.س489.1m (74% of total expenses). Explore how 4004's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 13% growth forecast for the Healthcare industry in Saudi Arabia.

Performance of the Saudi Healthcare industry.

The company's shares are down 1.4% from a week ago.

Risk Analysis

It is worth noting though that we have found 1 warning sign for Dallah Healthcare that you need to take into consideration.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.